Qingqing Ding, M.D., Ph.D.
Department of Anatomical Pathology, Division of Pathology-Lab Medicine Div
About Dr. Qingqing Ding
I am a surgical pathologist with expertise in diagnosing all kinds of breast tumor. I have a broad background in basic and clinic cancer research, with specific training and expertise in tumor signaling transduction and tumor markers. My previous studies focused on the underling mechanisms of important clinical questions such as HER2-caused breast cancer chemoresistance, HBV-related hepatocellular carcinoma, colon cancer liver metastasis, Barrett’s esophagus-associated esophageal adenocarcinoma, et al. My current studies include translational and clinical studies in breast cancer such as sensitive and specific breast marker TRPS1, radiation-induced angiosarcoma, and molecular characters of malignant phyllodes tumor.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Pathology, Division of Pathology-Lab Medicine Div, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2001 | Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, Ph.D. in Clinical Medicine |
| 1995 | Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, MD |
Postgraduate Training
| 2015-2017 | Clinical Fellowship, Surgical Pathology and Breast Pathology, MD Anderson Cancer Center, Houston, Texas |
| 2011-2015 | Clinical Residency, Anatomic and Clinic Pathology, University of Missouri, Columbia, Missouri |
| 2001-2005 | Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Licenses & Certifications
| 2017 | Texas Medical Board License |
| 2015 | American Board of Pathology |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2022
Assistant Professor, Department of Pathology/Laboratory Medicine, The University of Kansas Medical Center, Kansas, KS, 2017 - 2018
Assistant Professor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2011
Instructor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2008
Administrative Appointments/Responsibilities
Section chief, autopsy, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Medical director, ITB, Department of Institutional Tissue Bank, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Extramural Institutional Committee Activities
Member, Faculty Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Honors & Awards
| 2023 | Andrew Sabin Family Fellow Award, Andrew Sabin Family Foundation |
| 2021 | The Shirley Stein Scientific Endowed Award, The University of Texas MD Anderson Cancer Center |
| 2017 | The Sheskey Family Fellowship award for Breast Cancer Research, The university of Texas MD Anderson Cancer Center |
| 2016 | Breast pathology Mentioned Award, International Society of Breast Pathology |
| 2016 | The Bristol-Myers Squibb Award in Clinical Research, The university of Texas MD Anderson Cancer Center |
| 2009 | Career Development Research Award, NCI-MDACC Breast Cancer SPORE |
| 2001 | Outstanding Doctoral Graduate Award, Tongji Medical College |
| 1995 | Outstanding Medical Graduate Award, Tongji Medical College |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2025. Immunohistochemical Profiling of SLUG and ZEB1 in Metaplastic Breast Carcinoma: Insights into Histological Variability. Conference. 2025 USCAP annual meeting. Boston, MA, US.
- 2025. GATA3 and TRPS1 Expression in Follicular Dendritic Cell Sarcoma. Conference. 2025 USCAP annual meeting. Boston, MA, US.
- 2025. Granulomatous Lobular Mastitis due to Corynebacterium kroppenstedtii: Tissue Specificity, Pathogenesis, Microbiologic Workup and Treatment. Conference. 2025 USCAP annual meeting. Boston, MA, US.
- 2025. A Comparison of Three TRPS1 Antibodies in Detecting TRPS1 Expression in Breast Carcinoma and Ovarian Serous Carcinoma. Conference. 2025 USCAP annual meeting. Boston, MA, US.
- 2025. ESR1 Mutated Advanced Breast Cancer: Clinicopathological and Molecular Characteristics. Conference. 2025 USCAP annual meeting. Boston, MA, US.
- 2025. B72.3 Serves as a New Diagnostic Marker for Testicular Leydig Cell Tumor. Conference. 2025 USCAP annual meeting. Boston, MA, US.
- 2024. Predictive Biomarkers for Immune Checkpoint Inhibitor (ICI) and Poly (ADP-Ribose) Polymerase (PARP) Inhibitor (PARPi) in Advanced Stage Breast Carcinoma. USCAP Annual Meeting. Baltimore, MD, US.
- 2024. Differential Expression of SOX17 in Clear Cell Adenocarcinoma of the Genitourinary and Gynecologic Tracts. USCAP Annual Meeting. Baltimore, MD, US.
- 2024. Identifying Mesonephric-like Adenocarcinoma of the Endometrium by Combining SOX17 and PAX8 Immunohistochemistry. USCAP Annual Meeting. Baltimore, MD, US.
- 2024. SMARCA4/BRG1 Deficiency in Breast Carcinoma by Immunohistochemistry Study. USCAP Annual Meeting. Baltimore, MD, US.
- 2024. Spatial Transcriptomic Profiling of Cardiac Tissues from Dilated Cardiomyopathy Patients. USCAP Annual Meeting. Baltimore, MD, US.
- 2024. A Prospective Study of Real Time Whole Slide Imaging of Frozen Sections for Intraoperative Evaluation of Axillary Sentinel Lymph Nodes in Breast Cancer. USCAP Annual Meeting. Baltimore, MD, US.
- 2023. Comparative Transcriptomic Analyses Distinguish Cutaneous Squamoid Eccrine Ductal Carcinomas from Low-Grade Adenosquamous Carcinomas of the Breast. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2023. PD-L1 Expression by Immunohistochemistry: Comparison Between Tissue Microarrays and Whole Slide Sections in Breast Carcinoma. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2023. A Comparative Evaluation of TRPS1 and GATA3 in Adenoid Cystic, Acinic Cell, and Secretory Carcinomas of the Breast and Salivary Glands. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2023. BRCA status and clinicopathological characteristics in Mexican patients with invasive breast cancer and high risk of hereditary carcinoma. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2023. Nuclear Staining for Pan-Trk by Immunohistochemistry Is Highly Specific for Secretory Carcinoma: Pan-Trk in Various Subtypes of Breast Carcinoma,. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2023. TRPS1 May be an Effective Discriminatory Marker for Basal Cell Carcinoma and Squamous Cell Carcinoma: An Immunohistochemical Analysis of TRPS1 in Non-Melanocytic Cutaneous Neoplasms. USCAP Annual Meeting. New Orleans, MD, US.
- 2023. Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced Stage Breast Carcinoma. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2023. Nuclear Staining for Pan-Trk by Immunohistochemistry Is Highly Specific for Secretory Carcinoma: Pan-Trk in Various Subtypes of Breast Carcinoma. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2023. Comprehensive Clinical-Pathologic Assessment of Malignant Phyllodes Tumors: Proposing Refined Diagnostic Criteria. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2023. Immunohistochemical Assessment of HER2-Low Breast Cancer: Interobserver Reproducibility and Correlation with Digital Image Analysis. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2023. Prognostic Impact of NOTCH1 Expression in Primary Breast Adenoid Cystic Carcinoma. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2023. TRPS1 expression in metastatic mammary and non-mammary tumors of Mullerian and pulmonary origin by immunohistochemistry using cytology specimens. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2023. TRPS1 Expression in Neuroendocrine Neoplasms of Breast and Other Organs. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2023. Comparison of HER2 Scores by Immunohistochemistry and Oncotype DX. USCAP Annual Meeting. New Orleans, Louisiana, US.
- 2022. Specific Expression of SOX17 in Tumors of Mullerian Origin. Conference. Specific Expression of SOX17 in Tumors of Mullerian Origin. Los Angeles, CA, US.
- 2022. TRPS1 Expression in Invasive Ductal Carcinoma with Apocrine Features. Conference. TRPS1 Expression in Invasive Ductal Carcinoma with Apocrine Features. Los Angeles, CA, US.
- 2022. Establishing mammary origin for metastasis of unknown primary, ASCP Annual Meeting. Conference. Establishing mammary origin for metastasis of unknown primary, ASCP Annual Meeting. Chicago, IL, US.
- 2022. Expression of TRPS1, SOX10 and GATA3 in triple negative, invasive breast carcinomas of no special type and invasive lobular carcinomas. Conference. Expression of TRPS1, SOX10 and GATA3 in triple negative, invasive breast carcinomas of no special type and invasive lobular carcinomas. Los Angeles, CA, US.
- 2022. Expression of TRPS1, SOX10 and GATA3 in Different Subtypes of Metaplastic Breast Carcinoma. Conference. Expression of TRPS1, SOX10 and GATA3 in Different Subtypes of Metaplastic Breast Carcinoma. Los Angeles, CA, US.
- 2022. TRPS1 Expression in Male Breast Cancer. Conference. TRPS1 Expression in Male Breast Cancer. Los Angeles, CA, US.
- 2022. TRPS1 Expression is Frequently Seen in Mammary and Extramammary Paget Diseases, Except for Those Arising in the Perianal Skin, and Their Close Histologic Mimics including Squamous Cell Carcinoma in Situ with Pagetoid Pattern of Growth. Conference. TRPS1 Expression is Frequently Seen in Mammary and Extramammary Paget Diseases, Except for Those Arising in the Perianal Skin, and Their Close Histologic Mimics including Squamous Cell Carcinoma in Situ with Pagetoid Pattern of Growth. Los Angeles, CA, US.
- 2022. TRPS1 and GATA3 Expression in Adenoid Cystic Carcinoma of the Breast. Conference. TRPS1 and GATA3 Expression in Adenoid Cystic Carcinoma of the Breast. Los Angeles, CA, US.
- 2021. PTEN Alteration in ER+ Breast Cancer: Correlative Study of Immunohistochemistry and Next Generation Sequencing. Conference. PTEN Alteration in ER+ Breast Cancer: Correlative Study of Immunohistochemistry and Next Generation Sequencing, US.
- 2021. MYB Expression by Immunohistochemistry is Highly Specific and Sensitive for Detection of Solid Variant of Adenoid Cystic Carcinoma of the Breast, amidst all Triple Negative Breast Cancers. Conference. MYB Expression by Immunohistochemistry is Highly Specific and Sensitive for Detection of Solid Variant of Adenoid Cystic Carcinoma of the Breast, amidst all Triple Negative Breast Cancers, US.
- 2020. Comparison of Three FDA Approved PD-L1 Immunohistochemistry Assays in Triple Negative Breast Carcinoma. Conference. Comparison of Three FDA Approved PD-L1 Immunohistochemistry Assays in Triple Negative Breast Carcinoma. Los Angeles, CA, US.
- 2020. Clinicopathological Features of HER2-Positive Classic Invasive Lobular Carcinoma. Conference. Clinicopathological Features of HER2-Positive Classic Invasive Lobular Carcinoma. Los Angeles, CA, US.
- 2019. Retrospective analysis of 158 breast cancer case of group 4 HER2 FISH. Conference. Retrospective analysis of 158 breast cancer case of group 4 HER2 FISH. National Harbor, MD, US.
- 2017. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathologic features. Conference. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathologic features. San Antonio, TX, US.
- 2017. EZH2 Overexpression in Breast Cancer: Strong Correlation with HER2 Overexpression. Conference. EZH2 Overexpression in Breast Cancer: Strong Correlation with HER2 Overexpression. San Antonio, TX, US.
- 2016. MicroRNA profiling of malignant mesothelioma: Diagnostic significance in cytology specimens. Conference. MicroRNA profiling of malignant mesothelioma: Diagnostic significance in cytology specimens. Seattle, WA, US.
- 2016. Nomogram to predict pathologic complete response after neoadjuvant chemotherapy plus trastuzumab in HER2+ breast cancers. Conference. Nomogram to predict pathologic complete response after neoadjuvant chemotherapy plus trastuzumab in HER2+ breast cancers. Seattle, WA, US.
- 2016. Decreased expression of miR-26b in advanced breast cancer. Conference. Decreased expression of miR-26b in advanced breast cancer. Seattle, WA, US.
- 2015. Expression of antiapoptotic protein Mcl-1 correlates with HBV-X protein and tumor stage of human hepatocellular carcinoma. Conference. Expression of antiapoptotic protein Mcl-1 correlates with HBV-X protein and tumor stage of human hepatocellular carcinoma. Long Beach, CA, US.
- 2014. miRNA 148a is highly expressed in malignant mesothelioma. Conference. miRNA 148a is highly expressed in malignant mesothelioma. Tampa, FL, US.
- 2014. Angiomyomatous hamartomas is associated with dermatopathic lymphadenopathy. Conference. Tampa, FL, US.
- 2014. AREG expression is associated with poor survival of lung and gastric adenocarcinoma patients. Conference. AREG expression is associated with poor survival of lung and gastric adenocarcinoma patients. San Diego, CA, US.
- 2009. Downregulation of Mcl-1 through inhibiting Erk/Pin 1 pathway by Sorafenib facilitates chemosensitization in breast cancer. Conference. Downregulation of Mcl-1 through inhibiting Erk/Pin 1 pathway by Sorafenib facilitates chemosensitization in breast cancer. Denver, CO, US.
- 2008. Genes that mediate colon cancer metastasis to liver. Conference. Genes that mediate colon cancer metastasis to liver. Chicago, IL, US.
- 2007. Mcl-1 inversely correlates with GSK-3 activity and associates with poor prognosis in human breast cancer. Conference. Mcl-1 inversely correlates with GSK-3 activity and associates with poor prognosis in human breast cancer. Los Angeles, CA, US.
- 2006. Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant. Conference. Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant. Washington DC, US.
- 2005. Targeted pancreatic cancer-specific gene therapy controlled by a molecular-engineered human cholecystokinin type-A receptor (CCKAR) promoter in In Vivo imaging models. Conference. Targeted pancreatic cancer-specific gene therapy controlled by a molecular-engineered human cholecystokinin type-A receptor (CCKAR) promoter in In Vivo imaging models. St Louis, MO, US.
- 2005. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of Beta-catenin. Conference. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of Beta-catenin. Anaheim, CA, US.
International Presentations
- 2018. PD-L1 expression (clone 22C3) and tumor infiltrating lymphocytes in primary invasive breast cancer. Conference. PD-L1 expression (clone 22C3) and tumor infiltrating lymphocytes in primary invasive breast cancer. Vancouver, CA.
- 2018. PD-L1 Expression (clone 28-8) and Tumor Infiltrating Lymphocytes in Primary Invasive Breast Cancer. Conference. PD-L1 Expression (clone 28-8) and Tumor Infiltrating Lymphocytes in Primary Invasive Breast Cancer. Vancouver, CA.
Formal Peers
- 2022. Diagnostic markers for primary and metastatic breast carcinoma. Invited. Houston, TX, US.
- 2022. Diagnostic markers for triple negative breast carcinoma. Invited. Houston, TX, US.
- 2022. TRPS1: a highly sensitive and specific marker for breast carcinoma. Invited, US.
- 2021. Triple negative breast cancer and novel breast marker TRPS1. Invited. Houston, TX, US.
- 2021. Triple negative breast cancer and breast marker. Invited. Houston, TX, US.
- 2018. Papillary carcinoma of the breast. Invited. Kansas City, US.
- 2017. Triple negative breast cancer. Invited. Wuhan, CN.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | A novel MELK-DKK1 Axis Regulates Cancer Stemness in Aggressive Breast Cancers |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP26647 |
| Date: | 2026 - 2031 |
| Title: | Computational Approaches to Reconstruct the Evolutionary History of Cancer Metastases |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01CA299449 |
| Date: | 2023 - 2025 |
| Title: | Exploring the nature of malignant phyllodes tumor with comparison to metaplastic breast carcinoma and primary breast sarcoma |
| Funding Source: | Andrew Sabin Family Foundation |
| Role: | PI |
| ID: | Andrew Sabin Family Foundation |
| Date: | 2020 - Present |
| Title: | Identifying molecular risk factor for post-radiation angiosarcoma of the breast |
| Funding Source: | MDACC Department of Pathology junior faculty grant |
| Role: | PI |
| Date: | 2020 - Present |
| Title: | Targeted treatment on breast cancer with concurrent HER2 and PIK3CA mutation |
| Funding Source: | MDACC Division of Pathology and Laboratory Medicine Supplemental Research Funds |
| Role: | PI |
| Date: | 2019 - 2020 |
| Title: | TRPS1 is a novel biomarker for triple negative breast cancer |
| Funding Source: | MDACC Division of Pathology and Laboratory Medicine Research Award |
| Role: | PI |
| Date: | 2019 - 2022 |
| Title: | HER2 mutation in breast cancer |
| Funding Source: | MDACC Department of Pathology Seed Grant |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | Comparison of FDA approved PD-L1 immunohistochemistry assays in breast cancer |
| Funding Source: | MDACC Division of Pathology and Laboratory Medicine Research Grant |
| Role: | PI |
| Date: | 2009 - 2010 |
| Title: | Targeted therapy and prevention for obesity-mediated breast cancer |
| Funding Source: | NCI-MDACC Breast Cancer SPORE |
| Role: | PI |
| ID: | 5 P50 CA116199 05(PC-CDP 15) |
| Date: | 2005 - 2011 |
| Title: | Genetic factors in hepatocellular carcinoma |
| Funding Source: | Kadoorie Charitable Foundation |
| Role: | Co-I |
| Title: | Targeting the novel DNA break-induced replication (BIR) repair mechanism to selectively enhance replication catastrophe and induce innate immune responses with PARP inhibitor therapy |
| Funding Source: | NCI |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Ye Q, Estrella J, Kalhor N, Liu A, Han C, Sun H, Middleton LP, Chen H, Albarracin C, Sahin A, Wu Y, Ding Q. TRPS1 expression in neuroendocrine neoplasms of breast and other organs. Histopathology, 2025. e-Pub 2025. PMID: 41025885.
- Zheng L, He LJ, Chen H, Ding Q, Bishop J, Peng Y. CIC-rearranged sarcoma in the breast: A series of 3 rare cases with literature review. Hum Pathol 162:105801, 2025. e-Pub 2025. PMID: 40398821.
- Chen MK, Yamaguchi H, Gao Y, Xia W, Chang JT, Hsiao YC, Shegute TW, Lin ZS, Wu CS, Wang YH, Litton JK, Ding Q, Wei Y, Chu YY, Meric-Bernstam F, Piwnica-Worms H, Arun B, Rodon Ahnert J, Liu J, Yao J, Chang WC, Wang HL, Tapia C, Albarracin CT, Keyomarsi K, Wang SC, Wang YN, Hortobagyi GN, Lin C, Yang L, Yu D, Hung MC. FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models. J Clin Invest 135(14), 2025. e-Pub 2025. PMID: 40460005.
- Wang L, El-Naggar AK, Ding Q, Yu W, Middleton LP. Pattern of SOX9 expression in pleomorphic adenoma, carcinoma ex pleomorphic adenoma, and matrix-producing metaplastic carcinoma of the breast lends support to common biology. Virchows Arch, 2025. e-Pub 2025. PMID: 40583066.
- Anderson, SA, Bartow, BB, Siegal, GP, Harada, S, Yalniz, C, Khoury, K, Huo, L, Ding, Q, Sahin, AA, Wei, S, Huang, X. Predictive biomarkers for immune checkpoint inhibitor (ICI) and poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) in advanced-stage breast carcinoma. Human Pathology Reports 40, 2025. e-Pub 2025.
- Ding Q, Aung PP, Sun H, Soto LMS, Lu W, Raso MG, Rizvi YQ, Wistuba II, Sahin AA, Prieto VG. Upregulation of MMP9 expression in postradiation angiosarcoma of the breast: a possible predictive risk factor. Virchows Arch, 2025. e-Pub 2025. PMID: 40335788.
- Zheng L, Tabet G, Guo CC, Rizvi YO, Raso MG, Liu J, Ding Q, Baraban E, Zhao J. Clinicopathological study of 34 cases of clear cell adenocarcinoma of the urinary tract and diagnostic value of SOX 17 in its differential diagnosis. Hum Pathol 157(105767), 2025. PMID: 40189026.
- Gan Q, Ding Y, Wu Y, Zhang Y, Meng QH, Ding QQ, Lu H, Shelburne SA, Ehlersnd RA, Han XY. Infections Due to Corynebacterium kroppenstedtii With Focus on Granulomatous Lobular Mastitis for Tissue Specificity, Pathogenesis, Bacteriologic Workup, and Treatment. Arch Pathol Lab Med 149(9):812-821, 2025. PMID: 39800878.
- Ye, Q, Law, T, Klippel, D, Albarracin, C, Chen, H, Contreras, A, Ding, Q, Huo, L, Khazai, L, Middleton, LP, Resetkova, E, Sahin, AA, Sun, H, Sweeney, K, Symmans, WF, Wu, Y, Yoon, EC, Krishnamurthy, S. Prospective and Retrospective Analysis of Whole-Slide Images of Sentinel and Targeted Lymph Node Frozen Sections in Breast Cancer. Mod Pathol 38(4), 2025. PMID: 39788205.
- Ye Q, Chen H, Han C, Peng Y, Huang X, Sun H, Wu Y, Albarracin CT, Middleton LP, Sahin AA, Huo L, Ding Q. Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol 77(11):751-755, 2024. e-Pub 2024. PMID: 37586834.
- Yam C, Patel M, Hill HA, Sun R, Bassett RL Jr, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding Q, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun 4(10):2823-2834, 2024. e-Pub 2024. PMID: 39356138.
- Donthi D, Gan Q, Ding Q, Krishnamurthy S. Trichorhinophalangeal syndrome 1 expression in breast and nonbreast metastases from Mullerian, lung, gastrointestinal tract, and pancreatic primary tumors by immunohistochemistry with cytology cell block specimens. Cancer Cytopathol 132(12):799-808, 2024. e-Pub 2024. PMID: 39264831.
- Tahir M, Xing D, Ding Q, Wang Y, Singh K, Suarez AA, Parwani A, Li Z. Identifying mesonephric-like adenocarcinoma of the endometrium by combining SOX17 and PAX8 immunohistochemistry. Histopathology 86(2):268-277, 2024. e-Pub 2024. PMID: 39233315.
- Liang TZ, Ding Q, Middleton LP, Wu Y, Sahin AA. Characteristics of secretory breast carcinoma with extensive in situ carcinoma components. Human Pathology Reports 37, 2024. e-Pub 2024.
- Lim B, Seth S, Yam C, Huo L, Fujii, T, Lee J, Bassett Jr R, Nasser S, Ravenberg L, White JB, Clayborn A, Guerra G, Litton J, Damodaran S, Layman RM, Valero V, Tripathy D, Lewis MT, Dobrolecki, LE, Lei JT, Candelaria RP, Arun BK, Rauch GM, Zhao L, Zhang J, Ding Q, Symmans WF, Chang J, Thompson A, Moulder S, Ueno NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC. Cell Reports Medicine 5(6), 2024. e-Pub 2024. PMID: 38838676.
- Sun H, Kang EY, Chen H, Sweeney K, Suchko M, Wu Y, Wen J, Krishnamurthy S, Albarracin C, Ding Q, Foo WC, Sahin AA. Immunohistochemical assessment of HER2 low breast cancer. Breast Cancer Research and Treatment 205(2):403-411, 2024. e-Pub 2024. PMID: 38441847.
- Guirguis MS, Arribas E, Kapoor MM, Patel MM, Perez F, Nia ES, Ding Q, Moseley T, Adrada BE. Multimodality Imaging of Benign and Malignant Diseases of the Nipple-Areolar Complex. Radiographics 44(4), 2024. e-Pub 2024. PMID: 38483829.
- Salem A, Wu Y, Ding Q, Middleton LP. Impact of NOTCH1 expression in primary breast adenoid cystic carcinoma. J Clin Pathol 78(8):548-553, 2024. e-Pub 2024. PMID: 38471758.
- Salem A, Wu Y, Albarracin C, Middleton LP, Kalhor N, Peng Y, Huang X, Aung PP, Chen H, Sahin AA, Ding Q. A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland. Human Pathology 145:42-47, 2024. e-Pub 2024. PMID: 38262580.
- Wang J, Peng Y, Sun H, Aung PP, Resetkova E, Yam C, Sahin AA, Huo L, Ding Q. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation. Arch Pathol Lab Med 148(2):200-205, 2024. e-Pub 2023. PMID: 37074839.
- Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose D, Wistuba II, Fuller GN, Ballester L, Roy Chowdhuri S, Sweeney K, Rashid A, Yang RK, Chen W, Liu A, Wu Y, Albarracin C, Patel KP, Routbort MJ, Sahin AA, Ding Q, Chen H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers 16(1), 2024. e-Pub 2024. PMID: 38201434.
- Wang J, Chen H, Koenig J, Wu Y, Bedrosian I, Arun B, Ding Q, Khazai L, Resetkova E, Huo L, Sneige N, Albarracin C. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Research and Treatment 203(1):73-83, 2024. e-Pub 2024. PMID: 37751078.
- Liu YA, Aung PP, Wang Y, Ning J, Nagarajan P, Curry JL, Torres Cabala CA, Ivan D, Prieto V, Ding Q, Cho WC. TRPS1 expression in non-melanocytic cutaneous neoplasms. Journal of Pathology and Translational Medicine 58(2):72-80, 2024. e-Pub 2024. PMID: 38389280.
- Batra H, Ding Q, Pandurengan RK, Ibarguen H, Rabassedas NB, Sahin AA, Wistuba II, Parra Cuentas ER, Raso G. Exploration of cancer associated fibroblasts phenotypes in the tumor microenvironment of classical and pleomorphic Invasive Lobular Carcinoma. Frontiers in Oncology 13, 2023. e-Pub 2023. PMID: 38192631.
- Yang L, Lin Y, Shen Y, Roy M, Albarracin C, Ding Q, Huo L, Chen H, Wei B, Bu H, Bedrosian I, Wu Y. Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast. Breast Cancer Research and Treatment 202(1):23-32, 2023. e-Pub 2023. PMID: 37566192.
- Uzunparmak B, Haymaker CL, Raso G, Masciari S, Wang LI, Lin Y, Gorur A, Kirby B, Cimo AM, Kennon A, Ding Q, Urschel G, Yuan Y, Feng G, Rizvi YQ, Hussain A, Zhu C, Kim P, Abbadessa, G, Subbiah V, Yap TA, Rodon Ahnert J, Piha-Paul SA, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. Annals of Oncology 34(11):1035-1046, 2023. e-Pub 2023. PMID: 37619847.
- Turashvili G, Ding Q, Liu Y, Peng L, Mrkonjic M, Mejbel HA, Wang Y, Zhang H, Zhang G, Wang J, Wei S, Li X. Comprehensive Clinical-Pathologic Assessment of Malignant Phyllodes Tumors. American Journal of Surgical Pathology 47(11):1195-1206, 2023. e-Pub 2023. PMID: 37694517.
- Sun H, Ding Q, Sahin AA. Immunohistochemistry in the Diagnosis and Classification of Breast Tumors. Arch Pathol Lab Med, 2023. e-Pub 2023. PMID: 37490413.
- Sun, H, Ding, Q, Sahin, AA. Immunohistochemistry in the Diagnosis and Classification of Breast Tumors. Archives of Pathology and Laboratory Medicine 147(10):1119-1132, 2023. e-Pub 2023.
- Law T, Piotrowski MJ, Ning J, Jiang X, Ding Q, Sahin AA. Trichorhinophalangeal syndrome type 1 (TRPS1) expression in male breast carcinoma. Hum Pathol 138:62-67, 2023. e-Pub 2023. PMID: 37331526.
- Satturwar S, Shaker N, Sinclair W, Shen R, Parwani AV, Ding Q, Li Z. SOX17 is a highly sensitive and specific marker for metastatic ovarian and endometrial carcinomas in cytology cell block specimens. Cancer Cytopathol 131(7):465-470, 2023. e-Pub 2023. PMID: 37195085.
- Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
- Yam, C, Mittendorf, EA, Garber, HR, Sun, R, Damodaran, S, Murthy, RK, Ramirez, DL, Karuturi, MS, Layman, RM, Ibrahim, NK, Rauch, GM, Adrada, BE, Candelaria, RP, White, JB, Ravenberg, EE, Clayborn, A, Ding, Q, Symmans, WF, Prabhakaran, S, Thompson, A, Valero, V, Tripathy, D, Huo, L, Moulder, S, Litton, J. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Research and Treatment 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
- Wang M, Ding Q, Gu J, Sfamenos SM, Huo L, Tang Z, Sun H, Robinson M, Tang G, Lim B, Wu Y, Albarracin CT, Sahin AA, Chen H. Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?. Clin Breast Cancer 23(4):415-422, 2023. e-Pub 2023. PMID: 36878823.
- Cho WC, Ding Q, Wang WL, Nagarajan P, Curry JL, Torres-Cabala CA, Ivan D, Albarracin CT, Sahin A, Prieto VG, Aung PP. Immunohistochemical expression of TRPS1 in mammary Paget disease, extramammary Paget disease, and their close histopathologic mimics. J Cutan Pathol 50(5):434-440, 2023. e-Pub 2023. PMID: 36808637.
- Bartow BB, Siegal GP, Yalniz C, Elkhanany AM, Huo L, Ding Q, Sahin AA, Guo H, Magi-Galluzzi C, Harada S, Huang X. Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma. Cancers (Basel) 15(9), 2023. e-Pub 2023. PMID: 37173992.
- Zhang X, Yao J, Niu N, Li X, Liu Y, Huo L, Euscher ED, Wang H, Bell D, Sood AK, Wang G, Lawson BC, Ramalingam P, Malpica A, Sahin AA, Ding Q, Liu J. SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas. Mod Pathol 36(2):100001, 2023. e-Pub 2023. PMID: 36853778.
- Chen, H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton J, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson A, Mittendorf EA, Adrada BE, Virani K, White JB, Ravenberg EE, Song X, Candelaria RP, Arun BK, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim NK, Routbort MJ, Sahin AA, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma. Therapeutic Advances in Medical Oncology 15, 2023. e-Pub 2023. PMID: 37547448.
- Shaker N, Shafi S, Parkinson B, Chen W, Parwani AV, Ding Q, Li Z. Wnt Family Member 9b (Wnt9b) Is a Sensitive and Specific Marker for Triple-negative Breast Carcinoma Including Metaplastic Carcinoma. Am J Surg Pathol 47(1):47-54, 2023. e-Pub 2023. PMID: 36525542.
- Cho WC, Nagarajan P, Ding Q, Prieto VG, Torres-Cabala CA. Trichorhinophalangeal Syndrome Type 1-Positive Cells in Breast Dermal Granulation Tissues and Scars: A Potential Diagnostic Pitfall. Am J Dermatopathol 44(12):964-967, 2022. e-Pub 2022. PMID: 35925150.
- Shafi S, Hu Y, Parwani AV, Ding Q, Li Z. Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center. Breast Cancer Res Treat 196(3):463-469, 2022. e-Pub 2022. PMID: 36260193.
- Yoon EC, Wang G, Parkinson B, Huo L, Peng Y, Wang J, Salisbury T, Wu Y, Chen H, Albarracin CT, Resetkova E, Middleton LP, Krishnamurthy S, Gan Q, Sun H, Huang X, Shen T, Chen W, Parwani AV, Sahin AA, Li Z, Ding Q. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Hum Pathol 125:97-107, 2022. e-Pub 2022. PMID: 35413381.
- Yam C, Abuhadra N, Sun R, Adrada BE, Ding Q, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
- Shen T, Zhao J, Zhao M, Taggart MW, Ramalingam P, Gong Y, Wu Y, Liu H, Zhang J, Resetkova E, Wang WL, Ding Q, Huo L, Yoon E. Unusual staining of immunohistochemical markers PAX8 and CDX2 in breast carcinoma: a potential diagnostic pitfall. Hum Pathol 125:35-47, 2022. e-Pub 2022. PMID: 35417734.
- Zhou P, Chang N, Abraham SC, Albarracin CT, Huo L, Chen H, Ding Q, Resetkova E, Middleton LP, Sahin AA, Bu H, Wu Y. Metastatic nonhematopoietic neoplasms to the breast: a study of 238 cases. Hum Pathol 125:59-67, 2022. e-Pub 2022. PMID: 35447141.
- Wang J, Wang WL, Sun H, Huo L, Wu Y, Chen H, Gan Q, Meis JM, Maloney N, Lazar AJ, Yoon EC, Albarracin CT, Krishnamurthy S, Middleton LP, Resetkova E, Yu W, Tan D, Lu W, Solis Soto LM, Wang S, Wistuba II, Parwani AV, Prieto VG, Sahin AA, Li Z, Ding Q. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol 121:73-80, 2022. e-Pub 2022. PMID: 35063444.
- Guirguis MS, Checka C, Adrada BE, Whitman GJ, Dryden MJ, Sun J, Ding Q, Le-Petross H, Rauch GM, Clemens M, Moseley TW. Bracketing with Multiple Radioactive Seeds to Achieve Negative Margins in Breast Conservation Surgery: Multiple Seeds in Breast Surgery. Clin Breast Cancer 22(2):e158-e166, 2022. e-Pub 2022. PMID: 34187752.
- Huang X, Chen H, Ding Q, Robinson MK, Moseley TW, Bassett IRL, Tang G, Lim B, Sahin AA. Clinicopathological features of and neoadjuvant therapy for HER2-positive classic invasive lobular carcinoma. Hum Pathol 117:51-59, 2021. e-Pub 2021. PMID: 34363799.
- Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding Q, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res 27(19):5365-5375, 2021. e-Pub 2021. PMID: 34253579.
- Yang J, Wang J, Liu Y, Zhang Y, Huang W, Zou Y, Qiu Y, Cai W, Gao J, Zhou H, Wu Y, Liu W, Ding Q, Zhang Y, Yin PH, Tan W. PGE2-JNK signaling axis non-canonically promotes Gli activation by protecting Gli2 from ubiquitin-proteasomal degradation. Cell Death Dis 12(7):707, 2021. e-Pub 2021. PMID: 34267186.
- Li B, Pei G, Yao J, Ding Q, Jia P, Zhao Z. Cell-type deconvolution analysis identifies cancer-associated myofibroblast component as a poor prognostic factor in multiple cancer types. Oncogene 40(28):4686-4694, 2021. e-Pub 2021. PMID: 34140640.
- Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34(4):710-719, 2021. e-Pub 2021. PMID: 33011748.
- Huang X, Ding Q, Guo H, Gong Y, Zhao J, Zhao M, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma. Hum Pathol 108:42-50, 2021. e-Pub 2021. PMID: 33221342.
- Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res 22(1):69, 2020. e-Pub 2020. PMID: 32576238.
- Ding Q, Chen H, Lim B, Damodaran S, Chen W, Tripathy D, Piha-Paul S, Luthra R, Meric-Bernstam F, Sahin AA. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Hum Pathol 92:32-38, 2019. e-Pub 2019. PMID: 31351155.
- Li H, Li CW, Li X, Ding Q, Guo L, Liu S, Liu C, Lai CC, Hsu JM, Dong Q, Xia W, Hsu JL, Yamaguchi H, Du Y, Lai YJ, Sun X, Koller PB, Ye Q, Hung MC. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology 156(6):1849-1861.e13, 2019. e-Pub 2019. PMID: 30711629.
- Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li CW, Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, Cristofanilli M, Huo L. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol 77:121-129, 2018. e-Pub 2018. PMID: 29689244.
- Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell 30(6):925-939, 2016. e-Pub 2016. PMID: 27866850.
- Wang S, Zhang Y, Wang Y, Ye P, Li J, Li H, Ding Q, Xia J. Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis. J Biol Chem 291(40):21085-21095, 2016. e-Pub 2016. PMID: 27432879.
- Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun 7:12632, 2016. e-Pub 2016. PMID: 27572267.
- Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, Li LY, Lai CC, Chang SS, Hsu YH, Sun HL, Kim J, Yamaguchi H, Lee DF, Wang H, Wang Y, Chou CK, Hsu JM, Lai YJ, LaBaff AM, Ding Q, Ko HW, Tsai FJ, Tsai CH, Hortobagyi GN, Hung MC. AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res 76(6):1451-62, 2016. e-Pub 2016. PMID: 26759241.
- Wu X, Wang S, Han M, Song B, Ye P, Ma S, Li J, Chen F, Xu G, Ding Q, Xia J, Li H. Critical link between glycogen synthase kinase 3β and forkhead box P3 in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 136(6):1698-1700.e12, 2015. e-Pub 2015. PMID: 26431581.
- Spurgeon AN, Cress MC, Gabor O, Ding Q, Tanaka T, Miller DC. Oncogenic brain metazoan parasite infection. Case Rep Neurol Med 2013:263718, 2013. e-Pub 2013. PMID: 24151568.
- Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 21(3):374-87, 2012. e-Pub 2012. PMID: 22439934.
- Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, Yang MH, Hortobagyi GN, Hung MC. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res 72(5):1290-300, 2012. e-Pub 2012. PMID: 22253230.
- Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, Huo L, Cheng X, Chen YJ, Li CW, Jeng LB, Hsu JL, Li LY, Tan A, Curley SA, Ellis LM, Dubois RN, Hung MC. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest 121(11):4526-36, 2011. e-Pub 2011. PMID: 21985787.
- Huo L, Wang YN, Xia W, Hsu SC, Lai CC, Li LY, Chang WC, Wang Y, Hsu MC, Yu YL, Huang TH, Ding Q, Chen CH, Tsai CH, Hung MC. RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus. Proc Natl Asad Sci USA 107(37):16125-30, 2010. e-Pub 2010.
- Sun HL, Tsai AC, Pan SL, Ding Q, Yamaguchi H, Lin CN, Hung MC, Teng CM. EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation. Clin Cancer Res 15(15):4904-14, 2009. e-Pub 2009. PMID: 19622586.
- Song S, Mazurek N, Liu C, Sun Y, Ding Q, Liu K, Hung MC, Bresalier RS. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 69(4):1343-9, 2009. e-Pub 2009. PMID: 19190323.
- Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, Shen J, Chen CT, Huo LF, Hsu CH, Li JW, Ding Q, Liao LL, Lai CC, Lin AC, Chang YH, Tsai SF, Li LY, Hung MC. KEAP1 E3 ligase-mediated down-regulation of NF-κB signaling by targeting IKK. Molecular Cell 36(1):131-40, 2009. e-Pub 2009.
- Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ, Hsu JM, Kuo HP, Lin CY, Tsai FJ, Li LY, Tsai CH, Hung MC. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 68(15):6109-17, 2008. e-Pub 2008. PMID: 18676833.
- Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10(2):138-48, 2008. e-Pub 2008. PMID: 18204439.
- Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH, Hung MC. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130(3):440-55, 2007. e-Pub 2007. PMID: 17693255.
- Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY, Lee DF, Liu JC, Zhong Q, Wang X, Hung MC. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 27(11):4006-17, 2007. e-Pub 2007. PMID: 17387146.
- Ding Q, He X, Xia W, Hsu JM, Chen CT, Li LY, Lee DF, Yang JY, Xie X, Liu JC, Hung MC. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res 67(10):4564-71, 2007. e-Pub 2007. PMID: 17495324.
- Xie X, Xia W, Li Z, Kuo HP, Liu Y, Li Z, Ding Q, Zhang S, Spohn B, Yang Y, Wei Y, Lang JY, Evans DB, Chiao PJ, Abbruzzese JL, Hung MC. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 12(1):52-65, 2007. e-Pub 2007.
- Li Z, Ding Q, Li Y, Miller SA, Abbruzzese JL, Hung MC. Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant. Cancer Letters 236(1):58-63, 2006. e-Pub 2006.
- Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, Bartholomeusz G, Li Y, Pan Y, Li Z, Bargou RC, Qing J, Lai CC, Tsai FJ, Tsai CH, Hung MC. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Molecular Cell 19(2):159-170, 2005. e-Pub 2005.
- Li Y, Wen Y, Zhou B, Kuo HP, Ding Q, Hung MC. Enhancement of Bik antitumor effect by Bik mutants. Cancer Research 63(22):7630-7633, 2003. e-Pub 2003.
- Ding Q, Wu Z, Cheng X, al E. The effects of gene therapy on the experimental rabbit hepatocellular carcinoma by direct intratumoral or intrahepatic artery injection of HSV-TK gene. Chinese Journal of Experimental Surgery 20(11):989-991, 2003. e-Pub 2003.
- Ding Q, Wu Z, Chen L, al E. Combined Gene Therapy of HSV-TK and Wild-type P53 on the Experimental Hepatocellular Carcinoma. Chinese Journal of Experimental Surgery 19(4):345-347, 2002. e-Pub 2002.
- Ding Q, Wu Z, al E. Gene Therapy of HSV-TK Transferred by the EBV Based Expression Vector in the Experimental Hepatocellular Carcinoma . Journal of Tongji Medical University 21(2):122-125, 2001. e-Pub 2001.
- Ding Q, Wu Z. Progression of Strategy of Gene Therapy on Hepatocellular Carcinoma. Chinese Journal of Experimental Surgery 18(1):94-95, 2001. e-Pub 2001.
- Zhan Y, Ding Q, Wu Z, al E. The comparing investigation on the pDR2/TK gene injected the lobular blood vessels of the rat liver. Chinese Journal of Experimental Surgery 18(3):223-224, 2001. e-Pub 2001.
- Ding Q, Qin X, Yuan Y, al E. Clinicopathological Study on the Expression of p16 Protein in Thyroid Tumor. Chinese Journal of General Surgery 9(6):500-503, 2000. e-Pub 2000.
- Ding Q, Wu Z. Study of Targeting Gene Therapy on Hepatocellular Carcinoma. Foreign Medical Science (Fascicule of Surgery) 27(3):113-133, 2000. e-Pub 2000.
- Yuan Y, Ding Q, Jiang H, al E. Bcl-2 and p53 Protein Expression and Apoptosis in Pancreatic Cancer. World Chinese Journal of Digestology 7(100):851-854, 1999. e-Pub 1999.
- Ding Q, Qin X, al E. Expression of bcl-2 and p53 Protein in Thyroid Tumor. Chinese Journal of Clinical Oncology 26(3):188-190, 1999. e-Pub 1999.
- Ding Q, Tan J, Zhang L, al E. Effect of Neferine on Isolated Billiary Smooth Muscales. Journal of Tongji Medical University 25(4):264-267, 1996. e-Pub 1996.
Review Articles
- Sun H, Sahin AA, Ding Q. Updates on utility of immunohistochemistry in diagnosis of metastatic breast cancer. Hum Pathol 162:105821, 2025. e-Pub 2025. PMID: 40441446.
- Barrientos Toro, E, Ding, Q, Raso, G. Translational Aspects in Metaplastic Breast Carcinoma. Cancers 16(7), 2024. e-Pub 2024. PMID: 38611109.
- Batra, H, Mouabbi, JA, Ding, Q, Sahin, AA, Raso, G. Lobular Carcinoma of the Breast. Cancers 15(22), 2023. e-Pub 2023. PMID: 38001750.
- Ding Q, Huo L, Peng Y, Yoon EC, Li Z, Sahin AA. Immunohistochemical Markers for Distinguishing Metastatic Breast Carcinoma from Other Common Malignancies: Update and Revisit. Semin Diagn Pathol 39(5):313-321, 2022. e-Pub 2022. PMID: 35461734.
- Yoon E, Ding Q, Hunt K, Sahin A. High-Grade Spindle Cell Lesions of the Breast: Key Pathologic and Clinical Updates. Surg Pathol Clin 15(1):77-93, 2022. e-Pub 2022. PMID: 35236635.
- Crespo J, Sun H, Wu J, Ding Q, Tang G, Robinson MK, Chen H, Sahin AA, Lim B. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. PLoS One 15(11):e0241775, 2020. e-Pub 2020. PMID: 33180796.
Book Chapters
- Ding Q, Fan F. Ductal carcinoma in situ and Invasive breast carcinoma. In: Grossing, Staging, and Reporting. College of American Pathologist, 5-18, 2021.
Letters to the Editor
- Li Z, Ding Q, Xing D, Parwani AV. SOX17 expression in normal mesothelium and mesothelial lesions. Histopathology 87: 161-163, 2025.
Patient Reviews
CV information above last modified March 06, 2026